About Delfi Diagnostics
Delfi Diagnostics is a Healthcare company based in Baltimore (United States) founded in 2019. Provider of DNA sequencing for cancer detection. Delfi Diagnostics has raised $331.59 million across 6 funding rounds from investors including Lilly, Brown Advisory and TD Securities. Its chief executive, as recorded, is Susan Tousi. Delfi Diagnostics offers products and services including DELFI Method and CASCADE-LUNG Trial. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is DELFI DIAGNOSTICS, INC. Its competitors include Guardant Health, GRAIL and Natera; 3 of its 3 listed competitors have raised funding.
Company details
Delfi Diagnostics was founded in 2019 and is based in Baltimore, United States. Operations focus on the biotechnology sector, where a platform employing artificial intelligence and whole genome sequencing is utilized to identify DNA fragmentation patterns in patient blood samples. Services are centered on early cancer detection through non-invasive liquid biopsy methods, supporting diagnostic applications in oncology.
- Headquarters Baltimore, United States
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website delfidiagnostics.com
- Social LinkedIn X YouTube
- Legal Name Delfi Diagnostics, Inc.
- Total Equity Funding$331.59M (USD)
in 6 rounds
- Latest Funding Round$34.33M (USD), Debt – Conventional
Dec 2025
- InvestorsLilly
& 18 more
Products & Services of Delfi Diagnostics
Delfi Diagnostics offers a comprehensive portfolio of products and services, including DELFI Method and CASCADE-LUNG Trial.
Analyzes cell-free DNA fragments for early cancer screening.
Evaluates fragmentomics technology for lung cancer detection.
Apps and channels of Delfi Diagnostics
its YouTube channel DELFI Diagnostics has 34 subscribers and 6 videos.
Videos from Delfi Diagnostics
The most watched videos on Delfi Diagnostics's YouTube channel, DELFI Diagnostics (34 subscribers). Click a video to play it here.
More on DELFI Diagnostics.
Funding Insights of Delfi Diagnostics
Delfi Diagnostics has successfully raised a total of $331.59M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $34.33 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $331.59M
- Total Rounds 6
- Last Round Debt – Conventional — $34.33M
- First Round $15,343
(Jun 2018)
- Investors Count 19
All 6 funding rounds of Delfi Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $34.33M | Debt – Conventional | – | – | – |
| Jun 2024 | Series B | – | Merck Global Health Innovation Fund | – | |
| Jul 2022 | $225M | Series B | – | DFJ Growth | |
| Jan 2021 | $101.07M | Series A | – | Orbimed | |
| Jun 2019 | $5.5M | Seed | – | – | – |
| Jun 2018 | $15,343 | Seed | – | – | – |
19 investors in total: 19 institutional.
Investors in Delfi Diagnostics
Delfi Diagnostics has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Brown Advisory and TD Securities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are directed toward innovative technology startups by DFJ Growth. | dfjgrowth.com | Menlo Park, United States | ||
No specific business activity is described for this entity. | pointfieldpartners.com | |||
PTX Capital is involved in capital investment activities. | ptxcap.com | |||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Early-stage venture capital firm investing in AI, healthcare, and tech sectors. | menlovc.com | |||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Early-stage healthcare companies are funded and co-founded by INITIATE. | initiate.vc | |||
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Health tech startups are invested in by Illumina Ventures. | illuminaventures.com | Foster City, United States | ||
Early-stage startups are supported by AV8 Ventures through investments. | 2021 | av8.vc | Palo Alto, United States |
Investor details for Delfi Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Delfi Diagnostics
104 people are tracked at Delfi Diagnostics (49 in leadership, 13 in board & advisors, 42 in team).
| Name | Role | Group |
|---|---|---|
Susan Tousi | CEO | Leadership |
Kathryn Todd | Senior Director, Systems Engineering | Leadership |
Sumant Turlapati | Senior Director Of Software Engineering | Leadership |
Rob Scharpf | Head of Computational Biology & Co-Founder | Leadership |
David T. | Associate Director, Software Test And Test Automation | Leadership |
Renuka Ramachandran | Director Software Quality And Regulatory Compliance | Leadership |
Timothy McDaniel | VP, Technology Development | Leadership |
Victor Velculescu | CEO & Founder | Leadership |
Nicholas C. Dracopoli | Chief Scientific Officer & Co-Founder | Leadership |
Jenn Buechel | COO | Leadership |
Ally Dashner | Vice President & Head Of People | Leadership |
David Morgenstern | VP, Clinical Development | Leadership |
Kevin B Jacobs | Sr. Director, Software Engineering | Leadership |
Stephanie Curley | Associate Director, Automation Engineering | Leadership |
Robert Guigley | Chief Commercial Officer | Leadership |
Cindy Soriano | VP, Finance | Leadership |
Tom Russo | Chief Financial Officer | Leadership |
Craig Moraes | Sr. Director, Commercial Pipeline And Channel Initiatives | Leadership |
Nidhi Narang | VP Of SW And Data Engineering | Leadership |
Lee-Ann Smith-Freeman | VP, Legal | Leadership |
84 more people are available in the full profile.
Complete people profiles for Delfi Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Delfi Diagnostics
3 dated milestones of Delfi Diagnostics across 7 years, from founding to its latest funding, stage changes and deals.
- Funding First funding round of $15K.
- Founded Delfi Diagnostics is founded.
- Funding Latest funding round, Debt – Conventional, of $34.3M.
Competitors of Delfi Diagnostics
Delfi Diagnostics has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Natera.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health |
Detailed competitors of Delfi Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Delfi Diagnostics
The website of Delfi Diagnostics (delfidiagnostics.com) receives about 5.2K visits a month and ranks #3,035,678 among all websites worldwide, #4,026 in Biotechnology and Pharmaceuticals.
- Monthly visits5.2K
▼ 20.9% vs previous month
- Unique visitors2.8K
per month
- Global rank#3,035,678
among all websites
- Category rank#4,026
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit1.8
- Average visit27 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Delfi Diagnostics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| grail.com | 100% | 91K | #377,671 | View details | |
labpulse.com | labpulse.com | 60% | – | ||
| cityofhope.org | 55% | 408.6K | #145,358 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Delfi Diagnostics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Delfi Diagnostics
Complete news archive for Delfi Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Delfi Diagnostics
Delfi Diagnostics was founded in 2019.
Delfi Diagnostics is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Susan Tousi is the CEO of Delfi Diagnostics, as recorded in our data.
Delfi Diagnostics is a funded company, having raised a total of $331.59M across 6 funding rounds to date. The company's 1st funding round was a Seed of $15.34K, raised on Jun 2018.
Delfi Diagnostics was founded in 2019 and is based in Baltimore, United States. Operations focus on the biotechnology sector, where a platform employing artificial intelligence and whole genome sequencing is utilized to identify DNA fragmentation patterns in patient blood samples. Services are centered on early cancer detection through non-invasive liquid biopsy methods, supporting diagnostic applications in oncology.
Delfi Diagnostics's top competitors include Guardant Health, GRAIL and Natera.
Delfi Diagnostics offers DELFI Method and CASCADE-LUNG Trial.
Delfi Diagnostics has 19 investors. Key investors include Lilly, Brown Advisory, TD Securities, Orbimed, and DFJ Growth.
Delfi Diagnostics operates through Delfi Diagnostics, Inc..